摘要
Notch信号是许多器官包括肝脏生长和体内平衡的一条关键通路。异常的缺口信号被认为与癌症发展包括肝癌相关联。两个主要类型的肝癌肝细胞癌(HCC)和肝内胆管癌(IHCC)。超过80%的肝癌是HCCs,世界上第六最常见的恶性肿瘤。癌症肝细胞癌也带着很重的不良预后,是第三癌症相关死亡的常见原因。越来越多的证据表明,缺口信号在肝癌中的作用比曾经认为更复杂的,依赖于特定等级信号组件的表达和与其他信号通路复杂的串扰。目前有多种基于目标等级信号基因疗法包括中和抗体、siRNA、shRNA和microrna。针对anti-Notch疗法用于临床前研究中。将靶标性抗-Notch方法应用于临床仍然需要相当大的改进我们当前在调节Notch信号传导成分和他们在正常和恶性肝细胞的作用的知识,以确保能够针对特定的在肝癌发生过程中非常重要的Notch子单元,而不是正常细胞的体内平衡。使用这种方法会减少用GSIs治疗时患者的主要副作用,可能与抑制整个Notch信号通路相关。在这里我们综述了Notch信号,并强调了其在肝癌治疗的潜力。
关键词: 癌症治疗,干细胞癌,缺口信号,肿瘤启动,肿瘤进展
Current Gene Therapy
Title:Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Volume: 15 Issue: 2
Author(s): Guang Wu, George Wilson, Jacob George and Liang Qiao
Affiliation:
关键词: 癌症治疗,干细胞癌,缺口信号,肿瘤启动,肿瘤进展
摘要: Notch signaling is an evolutionarily conserved pathway crucial for the development and homeostasis of many organs including liver. Aberrant Notch signaling has been mechanistically linked to cancer development including liver cancer. The two principal types of liver cancer are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC). HCCs comprise over 80% of all liver cancers and are the 6th most common malignancy worldwide. Hepatocellular carcinoma is also a cancer with an extremely poor prognosis, being the 3rd commonest cause of cancer-related mortality. Accumulating evidence indicates that the role of Notch signaling in liver cancer is more complex than once thought and is dependent on the expression of specific Notch signaling components and the complex crosstalk with other signaling pathways. Currently there are a variety of gene therapy based approaches used to target Notch signaling in preclinical studies to successfully treat liver cancer including neutralizing antibodies, siRNA, shRNA and miRNA. The use of targeted anti-Notch therapy in the clinic to treat liver cancer will require considerable refinement of our current knowledge on the regulation of Notch signaling components and their effects in both normal and malignant liver cells in order to target specific Notch subunits which are critical to liver cancer tumorigenesis but not to the homeostasis of normal cells. Using this approach will reduce the major side effects, which are frequently seen in patients treated with GSIs to inhibit the entire Notch signaling pathway. Here our understanding of Notch signaling is reviewed, highlighting its function in liver cancer initiation, progress and opportunities for liver cancer therapies.
Export Options
About this article
Cite this article as:
Guang Wu, George Wilson, Jacob George and Liang Qiao , Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer, Current Gene Therapy 2015; 15 (2) . https://dx.doi.org/10.2174/1566523214666141224100319
DOI https://dx.doi.org/10.2174/1566523214666141224100319 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews SBRT for Liver Cancer
Current Cancer Therapy Reviews Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Current Medicinal Chemistry Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design